Bolt Biotherapeutics, Inc. (BOLT)

Market Cap	28.02M
Revenue (ttm)	11.32M
Net Income (ttm)	-63.03M
Shares Out	38.13M
EPS (ttm)	-1.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	40,576
Open	0.730
Previous Close	0.732
Day's Range	0.720 - 0.750
52-Week Range	0.720 - 1.560
Beta	0.93
Analysts	Hold
Price Target	1.25 (+70.07%)
Earnings Date	Aug 5, 2024

About BOLT

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 5, 2021
• Employees: 100
• Stock Exchange: NASDAQ
• Ticker Symbol: BOLT

Financial Performance

In 2023, BOLT's revenue was $7.88 million, an increase of 37.48% compared to the previous year's $5.73 million. Losses were -$69.20 million, -21.45% less than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for BOLT stock is "Hold." The 12-month stock price forecast is $1.25, which is an increase of 70.07% from the latest price.

Price Target

$1.25

(70.07% upside)

Analyst Consensus: Hold